Gene Fusion Detection Kit for Personalized Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current breast cancer diagnosis and treatment options are limited, with a need for more personalized approaches that can be tailored to individual patient's tumor characteristics, as existing methods do not adequately account for genetic variations such as gene fusions that may drive cancer progression.
Innovation Solution
The development of a kit and method for detecting specific gene fusions like SLC45A3-FGFR2, FGFR2-KIAA1967, FGFR2-OFD1, and FGF1-Bag4 in cancer patients, using reagents such as probes, primers, and antibodies to identify these fusions in biological samples, allowing for targeted therapy with pathway inhibitors based on their presence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional breast cancer diagnosis methods (mammography, ER/PR testing) are used, then early detection and basic treatment selection are achieved, but personalized treatment based on genetic variations cannot be provided
Solution Approach 1:
The patent segments the broad category of breast cancer into specific molecular subtypes based on gene fusion patterns (e.g., FGFR2 fusions, ETV6-NTRK3 fusions). By detecting specific gene fusion events rather than treating all breast cancers uniformly, the method enables personalized treatment strategies tailored to each patient's genetic profile, directly addressing the need for adaptability while capturing previously lost genetic information.
Solution Approach 2:
The patent introduces gene fusion detection assays as an intermediary between traditional diagnosis and personalized treatment selection. These assays serve as a bridge that translates genetic variation data into actionable treatment decisions, allowing clinicians to select targeted therapies (e.g., FGFR inhibitors for FGFR2 fusion-positive tumors) based on molecular characteristics rather than relying solely on traditional histological classification.
2Adaptability or versatility
If comprehensive gene fusion detection is implemented, then personalized treatment options are expanded, but diagnostic complexity and cost increase
Solution Approach 1:
The patent employs universal detection platforms (such as FISH assays and RT-PCR) that can identify multiple different gene fusion events using similar methodological approaches. Rather than requiring separate specialized tests for each gene fusion type, these multi-functional assays can screen for various fusion partners (FGFR2, NTRK3, EGFR, etc.) within a unified diagnostic workflow, thereby reducing overall system complexity while maintaining comprehensive detection capability.
Solution Approach 2:
The patent implements a tiered diagnostic approach where preliminary screening for gene fusions is performed using efficient methods (such as FISH or RNA-seq), and only samples that test positive or show suspicious patterns proceed to more comprehensive characterization. This preliminary action filters the patient population, reducing the need for complex follow-up testing in all cases and thereby lowering the average complexity burden while still enabling personalized treatment when needed.
3Measurement precision
If gene fusion detection is performed on all breast cancer patients, then treatment precision is improved, but time and resource consumption increase
Solution Approach 1:
The patent applies gene fusion detection selectively to specific patient populations or tumor subtypes where gene fusions are most likely to occur and have clinical impact (e.g., triple-negative breast cancers, metastatic disease, or tumors with specific histological features). By concentrating diagnostic resources on cases with highest probability of benefit, the method maintains high diagnostic accuracy for relevant cases while avoiding unnecessary testing in low-yield scenarios, thereby reducing overall time and resource consumption.
Solution Approach 2:
The patent implements a risk-stratified testing strategy where gene fusion detection is performed on a subset of patients identified as high-risk or high-benefit candidates based on clinical and pathological features. This partial action approach focuses intensive diagnostic efforts where they will have the greatest impact on treatment outcomes, rather than universally applying the most comprehensive testing to all patients, thus optimizing the balance between diagnostic precision and resource utilization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate detection of gene fusions associated with breast cancer and other cancers, facilitating personalized treatment decisions by identifying patients who may benefit from specific gene fusion pathway inhibitors, potentially improving treatment outcomes.
Implementation Method 1
the reagent is, for example, a probe that specifically hybridizes to the fusion junction of the gene fusion
Implementation Method 2
a pair of primers that amplify a fusion junction of the gene fusion
Implementation Method 3
an antibody that binds to the fusion junction of the gene fusion polypeptide
Data Source
AI summary
The present disclosure relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present disclosure relates to gene fusions as diagnostic markers and clinical targets for cancer.